secwatch.observer — SEC 8-K summary
======================================

Issuer:     TITAN PHARMACEUTICALS INC (—)
CIK:        0000910267
Form:       8-K
Filed at:   2023-04-11T23:59:59+00:00
Accession:  0001829126-23-002648
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 5.08, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Titan Pharma receives Nasdaq deficiency notice for stockholders' equity below $2.5M
--------------------------------------------------------------------------------

- Stockholders' equity of $1.363M as of Dec 31, 2022, below Nasdaq's $2.5M minimum.
- Company has 45 days to submit a compliance plan; may get up to 180 days to cure.
- 2022 annual meeting set for June 19, 2023; record date May 1, 2023.
- Shareholder proposals due by April 24, 2023 for inclusion in proxy materials.
- Listing on Nasdaq Capital Market unaffected for now while company evaluates options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/910267/000182912623002648/0001829126-23-002648-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/910267/000182912623002648/titanpharma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-23-002648

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer